Aardvark Therapeutics (NASDAQ:AARD) Earns Outperform Rating from Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Aardvark Therapeutics (NASDAQ:AARD) in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently has a $21.00 target price on the stock.

Several other analysts have also weighed in on the company. Cantor Fitzgerald reissued an “overweight” rating and set a $50.00 price objective on shares of Aardvark Therapeutics in a report on Tuesday. Bank of America lifted their target price on shares of Aardvark Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Thursday, March 27th. Finally, Morgan Stanley initiated coverage on shares of Aardvark Therapeutics in a research report on Monday, March 10th. They issued an “overweight” rating and a $29.00 price target for the company.

Aardvark Therapeutics Stock Performance

NASDAQ:AARD opened at $8.69 on Tuesday. Aardvark Therapeutics has a 52-week low of $6.79 and a 52-week high of $19.58.

Insiders Place Their Bets

In other Aardvark Therapeutics news, CFO Nelson Sun bought 10,000 shares of the business’s stock in a transaction on Friday, February 14th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $160,000.00. Following the transaction, the chief financial officer now owns 99,484 shares in the company, valued at approximately $1,591,744. This trade represents a 11.18 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Tien-Li Lee purchased 16,542 shares of the stock in a transaction dated Friday, February 14th. The shares were acquired at an average price of $16.00 per share, with a total value of $264,672.00. Following the transaction, the chief executive officer now owns 1,496,175 shares in the company, valued at $23,938,800. This trade represents a 1.12 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Aardvark Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.